5-HT2A Receptors
Serotonin 5-HT2A receptors, previously known as 5-HT2 receptors, are located primarily in the neocortex, caudate nucleus, nucleus accumbens, hippocampus, and vascular and non-vascular smooth muscle cells. 5-HT2A receptors play a role in the control of appetite.
5-HT2A Receptor Agonists |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 5171 | NBOH-2C-CN hydrochloride |
| High affinity and selective 5-HT2A agonist | |
| 2592 | TCB-2 |
| High affinity and potent 5-HT2A agonist | |
5-HT2A Receptor Inverse Agonists |
|
| Cat. No. | Product Name / Activity |
| 7667 | Pimavanserin |
| Selective 5-HT2A inverse agonist | |
5-HT2A Receptor Antagonists |
|
| Cat. No. | Product Name / Activity |
| 1809 | Altanserin hydrochloride |
| 5-HT2A receptor antagonist | |
| 5584 | Aripiprazole |
| 5-HT2A antagonist; also D2 and 5-HT1A receptor partial agonist | |
| 0444 | Clozapine |
| 5-HT2A and 5-HT2C antagonist; also dopamine antagonist | |
| 4470 | EMD 281014 hydrochloride |
| Selective 5-HT2A antagonist | |
| 4958 | Eplivanserin hemifumarate |
| Potent and selective 5-HT2A antagonist | |
| 0523 | 4F 4PP oxalate |
| Selective 5-HT2A antagonist | |
| 0908 | Ketanserin tartrate |
| Selective 5-HT2A antagonist. Also antagonist at 5-HT1D | |
| 4173 | MDL 100907 |
| Potent and selective 5-HT2A antagonist | |
| 0870 | MDL 11,939 |
| 5-HT2A antagonist | |
| 1644 | Mesulergine hydrochloride |
| 5-HT2A and 5-HT2C antagonist; also D2-like partial agonist | |
| 4349 | Olanzapine |
| 5-HT2A antagonist; also D2 antagonist; atypical antipsychotic | |
| 4493 | Paliperidone |
| 5-HT2A antagonist; also D2 antagonist; atypical antipsychotic | |
| 1742 | R-96544 hydrochloride |
| Potent, selective 5-HT2A antagonist | |
| 2865 | Risperidone |
| 5-HT2A antagonist; also D2 antagonist; atypical antipsychotic | |
| 3739 | Sarpogrelate hydrochloride |
| Selective 5-HT2A antagonist | |
| 6336 | Trazodone hydrochloride |
| 5-HT2A and α1 adrenoceptor antagonist; also enhances neural differentiation; antidepressant and neuroprotectant | |
Serotonin 5-HT2A receptors, previously known as 5-HT2 receptors, are located primarily in the neocortex, caudate nucleus, nucleus accumbens, hippocampus, and vascular and non-vascular smooth muscle cells. 5-HT2A receptors play a role in sleep and the control of appetite.
External sources of pharmacological information for 5-HT2A Receptors :
Literature for 5-HT2A Receptors
Tocris offers the following scientific literature for 5-HT2A Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Our 5-HT review summarizes the serotonin receptor subtypes and highlights their importance in mediating various physiological & pharmacological processes.
Request copyRequest PDFWritten by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF